Cost-effectiveness of eplerenone in treatment of cardio-vasculardiseases: a systematic review

Authors

  • Ali Sarabi Asiabar Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Aziz Rezapour Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Hossein Mobaraki Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
  • Saber Azami-Aghdash Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract:

Introduction: In recent years, a few studies have been conducted in the area of the cost-effectiveness of the Eplerenone; it's notable that coherent and clear evidence are not available. Therefore, this study aimed to systematically review studies of cost-effectiveness of Eplerenone in the treatment of cardio-vascular patients. Methods: This systematic review study was conducted in 2016. The required information were collected by using key Mesh words from databases such as: Google scholar, PubMed, Science Direct, MagIran, SID, Scopus and hand searching journals and selected articles references. The Quality of selected articles was assessed by the Drummond's check-list. Results: Nine articles were included from 296 articles found in literature review. Studies have been conducted in 8 countries (America, Britain, Australia, Switzerland, France, Spain, the Netherlands and Canada). In general, the cost-effectiveness of Eplerenone was investigated on 31757 in treating cardio-vascular patients. Average of quality-adjusted life years (QALY) in studies with non-modeling was equal to 0.0908 in terms of Framingham approach, 0.0595 in terms of Saskatchewan approach and 0.1309 in terms of Worcester approach. In general, the overall average cost of treating cardiovascular patients with Eplerenone was equal to $6694 of America in one year. The cost per additional (QALY) was estimated to be $ 9478 of America. Incremental cost-effectiveness ratio was high in the United States compared to European countries. The Average quality of articles was estimated about 7.4 from 10. Conclusion: Based on the results of the studies reviewed in this study, it seems that Eplerenone has acceptable cost-effectiveness compared with current treatments, placebo and similar drugs.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

cost-effectiveness of eplerenone in treatment of cardio-vasculardiseases: a systematic review

introduction: in recent years, a few studies have been conducted in the area of the cost-effectiveness of the eplerenone; it's notable that coherent and clear evidence are not available. therefore, this study aimed to systematically review studies of cost-effectiveness of eplerenone in the treatment of cardio-vascular patients. methods: this systematic review study was conducted in 2016. t...

full text

Cost-effectiveness of Eplerenone in treatment of cardiovascular diseases: a systematic review

Background: No clear evidence is available on the cost-effectiveness of eplerenone in treatment of cardiovascular diseases. Thus, the present study aimed at systematically reviewing studies that have investigated this issue. Methods: This systematic review study was conducted in 2016. The required information were collected using key Mesh words from the following databases: Google scholar, PubM...

full text

Cost effectiveness of type 2 diabetes screening: A systematic review

Background: Although studies reported diabetes mellitus screening cost effective, the mass screening for type2 diabetes remains controversial. In this study we reviewed the recently evidence about the cost effectiveness of mass screening systematically.   Methods: We reviewed the MEDLINE, Scopus, Web of Science (WOS), and Cochrane library databases by MeSH terms to identify relevan...

full text

cost effectiveness of anemia screening: a systematic review

background: anemia is the most common blood disorder observed in vulnerable groups and affects their efficiency in their everyday activities. possible complications of the disease may be reduced or prevented by screening of patients. screening programs impose certain costs upon the health system, which may offset their positive effects. whether the positive impacts of screening outweigh its cos...

full text

cost effectiveness of type 2 diabetes screening: a systematic review

background: although studies reported diabetes mellitus screening cost effective, the mass screening for type2 diabetes remains controversial. in this study we reviewed the recently evidence about the cost effectiveness of mass screening systematically.   methods: we reviewed the medline, scopus, web of science (wos), and cochrane library databases by mesh terms to identify relevant studies fro...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 31  issue 1

pages  13- 22

publication date 2017-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023